[Translation] An open-label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of H002 in patients with epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small cell lung cancer Phase I/IIa clinical study
评估H002的安全性和耐受性,并确定最大耐受剂量(MTD)或最佳生物效应剂量(OBD)/II期推荐剂量(RP2D)。评估H002口服给药的药代动力学(PK)特征。评估H002治疗的初步抗肿瘤作用。
[Translation] Evaluate the safety and tolerability of H002 and determine the maximum tolerated dose (MTD) or optimal biological effect dose (OBD)/phase II recommended dose (RP2D). To evaluate the pharmacokinetic (PK) profile of H002 administered orally. To evaluate the preliminary antitumor effect of H002 treatment.